← Back to overview

RVTY Revvity, Inc.

Health Care Equipment · $110.47 -2.39%
Price Alert:
Price & Volume
RSI (14)
MACD (12, 26, 9)

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
60.2
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
111.57 / 104.15 / —
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
2.04 / 2.57
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
53.1
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
12.32B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
0.25%
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
81.22 – 118.30
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Revvity, Inc. is trading at $110.47, -2.39% versus the previous close. The price sits roughly in the middle of its 52-week range.
RSI is in a neutral range — no strong overbought/oversold signal.
MACD is below its signal line — momentum currently leans negative.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs
Zacks · 2026-07-24 15:05
Revvity to Launch Signals for Startups for Emerging Biotech Companies
Zacks · 2026-07-22 15:04
Revvity Launches "Signals for Startups" to Help Emerging Biotechs Build Scalable Digital Foundations from Day One
Business Wire · 2026-07-20 12:00
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
Business Wire · 2026-07-20 12:00
TD Cowen Adjusts Price Target on Revvity to $130 From $120, Maintains Buy Rating
MT Newswires · 2026-07-15 15:26
Alamar Hits A High Note On Alzheimer's Buzz
Trefis · 2026-07-13 20:50
Baird Adjusts Price Target on Revvity to $128 From $117, Maintains Outperform Rating
MT Newswires · 2026-07-13 13:53
Should Revvity’s (RVTY) Claude Integration Reframe How Investors View Its Data and AI Strategy?
Simply Wall St. · 2026-07-10 00:17
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.